"Their commitment strengthens BOOST Pharma’s position as a leader in cell therapy for genetic bone disorders and enables continued progress of BT-101 towards the clinic." "We believe BOOST Pharma’s ...

The group alleges selective use of field trial results to project higher yields and early maturation while ICAR scientists defend the evaluation process as transparent and scientifically sound ...

This policy primer from the Allen Lab for Democracy Renovation is intended to introduce the ideas and conversations around reform of Section 230 of the Communications Decency Act and how it could ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial with the company’s cell ...

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

If you’re trying to conceive, learning about fertilisation makes the process less of a mystery. It highlights that conception ...

The impact of THC varies person to person, says Shields, who notes that the typical threshold to feel the effects of edibles is between 2 to 10 mg of THC, but some people have a higher dose threshold ...

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...

A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

Dyne Therapeutics, Inc. ((DYN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...